Logo

Nucleonics Wins $1.6M from NIAID for RNAi-Based Hep B Study

Sep 26, 2003

NEW YORK, Sept. 26 (GenomeWeb News) - Malvern, Pa.-based Nucleonics announced yesterday that it had received a four-year, $1.6 million grant from the National Institute of Allergy and Infectious Disease to develop RNAi reagents and methods against the Hepatitis B virus.

 

The company will collaborate with the Scripps Research Institute and the Doylestown, Pa.-based Hepatitis B Foundation on the project, which will be aimed toward the eventual development of a therapeutic for Hepatits B.

 

Nucleonics uses expressed interfering RNA, or eiRNA, for its gene silencing techniques.

 

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.